Although the mTOR pathway has been reported to be important for the viability and maintenance of breast and glioblastoma CSCs [34], [35], inhibition of mTOR with rapamycin in H-Ras-transformed mouse liver cancer cells significantly increased the proportion of CD133+ cells and retained the stemness properties. This evidence concerns the gene HRAS and liver cancer.